Cationic Hydroxyethyl Cellulose Nanocomplexes and RANK SiRNA/Zoledronate Co-Delivery Systems for Osteoclast Inhibition

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 8

PMID 39771601

Authors

Sohyun Lee

Seoyeon Park

Tae-Il Kim

Affiliations

Soon will be listed here.

Abstract

Background/objectives: In this study, HECP2k polymer, polyethylenimine2k (PEI2k)-modified hydroxyethyl cellulose (HEC) was utilized to form the nanocomplexes with receptor activator of nuclear factor k-B (RANK) siRNA and zoledronate (Zol) for osteoclast inhibition. HECP2k/(RANK siRNA + Zol) nanocomplexes prepared by simple mixing were anticipated to overcome the low transfection efficiency of siRNA and the low bioavailability of Zol.

Methods: The characterization of both HECP2k/(pDNA + Zol) nanocomplexes and HECP2k/(RANK siRNA + Zol) nanocomplexes was performed.

Results: The nanocomplexes were successfully formed even in the presence of Zol, showing about 200 nm sizes and about 20 mV of positive zeta potential values suitable for efficient cellular uptake. They also possessed high endosome buffering ability by PEI and Zol, suggesting the potential for efficient endosomal escape. It was found that the low cytotoxic nanocomplexes (>90% cell viability) displayed greater transfection efficiency than PEI25k and even HECP2k polyplexes. Finally, it was found by tartrate-resistant acid phosphatase (TRAP) assay and qPCR analysis that HECP2k/(RANK siRNA + Zol) nanocomplexes could inhibit the TRAP to about 50% value and another characteristic osteoclastic gene expression, increasing FAS gene expression to about 16 times higher than control and more efficiently (about 3 times and 5 times higher, respectively) than HECP2k/siRNA polyplexes and Zol only.

Conclusions: HECP2k/(RANK siRNA + Zol) nanocomplexes formed by simple mixing showed great potential for inhibiting osteoclast differentiation and osteoclast activity, inducing the apoptosis via combinatorial effects of RANK siRNA and Zol.

References

George E, Lin Y, Saunders M . Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Rep. 2018; 8:104-109. PMC: 6020112. DOI: 10.1016/j.bonr.2018.03.003. View

Gao Y, Xin H, Cai B, Wang L, Lv Q, Hou Y . RNA interference-based osteoanabolic therapy for osteoporosis by a bone-formation surface targeting delivery system. Biochem Biophys Res Commun. 2022; 601:86-92. DOI: 10.1016/j.bbrc.2022.02.080. View

Mora-Raimundo P, Lozano D, Manzano M, Vallet-Regi M . Nanoparticles to Knockdown Osteoporosis-Related Gene and Promote Osteogenic Marker Expression for Osteoporosis Treatment. ACS Nano. 2019; 13(5):5451-5464. PMC: 6588271. DOI: 10.1021/acsnano.9b00241. View

Shaw N, Bishop N . Bisphosphonate treatment of bone disease. Arch Dis Child. 2005; 90(5):494-9. PMC: 1720410. DOI: 10.1136/adc.2003.036590. View

Salamanna F, Gambardella A, Contartese D, Visani A, Fini M . Nano-Based Biomaterials as Drug Delivery Systems Against Osteoporosis: A Systematic Review of Preclinical and Clinical Evidence. Nanomaterials (Basel). 2021; 11(2). PMC: 7922277. DOI: 10.3390/nano11020530. View

Wang Y, Grainger D . siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption. Pharm Res. 2010; 27(7):1273-84. PMC: 2885461. DOI: 10.1007/s11095-010-0099-5. View

Li E, Davis L . Zoledronic acid: a new parenteral bisphosphonate. Clin Ther. 2003; 25(11):2669-708. DOI: 10.1016/s0149-2918(03)80327-2. View

Bilecen D, Uludag H, Hasirci V . Development of PEI-RANK siRNA Complex Loaded PLGA Nanocapsules for the Treatment of Osteoporosis. Tissue Eng Part A. 2018; 25(1-2):34-43. DOI: 10.1089/ten.TEA.2017.0476. View

Nishiguchi A, Taguchi T . Osteoclast-Responsive, Injectable Bone of Bisphosphonated-Nanocellulose that Regulates Osteoclast/Osteoblast Activity for Bone Regeneration. Biomacromolecules. 2019; 20(3):1385-1393. DOI: 10.1021/acs.biomac.8b01767. View

10.

Wang Y, Tran K, Shen H, Grainger D . Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials. Biomaterials. 2012; 33(33):8540-7. PMC: 3444628. DOI: 10.1016/j.biomaterials.2012.07.039. View

11.

Hayman A . Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 2008; 41(3):218-23. DOI: 10.1080/08916930701694667. View

12.

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

13.

Black D, Condra K, Adams A, Eastell R . Bisphosphonates and the risk of atypical femur fractures. Bone. 2021; 156:116297. DOI: 10.1016/j.bone.2021.116297. View

14.

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

15.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

16.

Park J, Kim K, Jeong S, Lee M, Kim T . Highly Osmotic Oxidized Sucrose-Crosslinked Polyethylenimine for Gene Delivery Systems. Pharmaceutics. 2021; 13(1). PMC: 7826834. DOI: 10.3390/pharmaceutics13010087. View

17.

Park J, Kim S, Kim T . Polyethylenimine-Conjugated Hydroxyethyl Cellulose for Doxorubicin/Bcl-2 siRNA Co-Delivery Systems. Pharmaceutics. 2023; 15(2). PMC: 9965717. DOI: 10.3390/pharmaceutics15020708. View

18.

Pack D, Putnam D, Langer R . Design of imidazole-containing endosomolytic biopolymers for gene delivery. Biotechnol Bioeng. 1999; 67(2):217-23. View

19.

Wang H, Luo Y, Wang H, Li F, Yu F, Ye L . Mechanistic advances in osteoporosis and anti-osteoporosis therapies. MedComm (2020). 2023; 4(3):e244. PMC: 10175743. DOI: 10.1002/mco2.244. View

20.

Kim J, Lin C, Stavre Z, Greenblatt M, Shim J . Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020; 9(9). PMC: 7564526. DOI: 10.3390/cells9092073. View